Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Difamilast in pediatric atopic dermatitis
NCT03018691Phase 2Completed
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
- Start
- Jan 2017
- Primary completion
- Jun 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of difamilast in atopic dermatitis (AD) (3 arms), sponsored by Otsuka Pharmaceutical Co., Ltd. Primary endpoint: Number of Subjects Experiencing Adverse Events. Started Jan 2017; status: completed.
02
Drugs
difamilast
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT03018691.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03018691.